$SWIM

Kunchala Suraj sold (to issuer) $63K of SWIM

Kunchala Suraj (VICE PRESIDENT & CONTROLLER) sold (to issuer) 8,693 shares of Latham Group, Inc. (SWIM) at $7.29 on 2026-08-07.

Original reporting
SEC EDGAR · Kunchala Suraj
Published Aug 11, 2026, 12:43 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SWIM
Neutral
low confidence
Mentioned
$SWIM
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SWIMNeutralLow
01

Why it matters

The only new information is the insider sale details (shares, price, total value, and post-transaction holdings). There is no accompanying corporate event or performance update.

02

Market read

For traders, this is primarily a monitoring datapoint on insider behavior rather than a catalyst for repricing.

03

What to watch

The transaction is coded as a sale to the issuer, which can be administrative (for example, buyback participation or similar mechanics) and may not reflect bearish fundamentals.

Relevance 3/10Novelty 2/10Timing: filed 2026-08-11 after-hours/market close window (per timestamp)

Background

The article is a SEC Form 4 insider transaction disclosure for Latham Group, Inc. (SWIM).

Company-level read

Ticker impact

$SWIMNeutralLow confidence
Context

Latham Group, Inc. (SWIM) disclosed an insider Form 4 sale to the issuer of 8,693 shares at $7.2900 on 2026-08-07.

Expected impact

Likely limited near-term impact; treat as low-signal unless follow-on filings show sustained selling or a change in insider behavior.

Evidence & confidence

The filing provides transaction details but does not include new guidance, earnings, contracts, or regulatory developments. Insider sales can be non-informational, and the article lacks context on motivation or broader insider activity.

Market effects

No clear sector read-through from a single insider sale to the issuer.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted as less routine, so traders may watch for additional insider selling or unusual volume around the filing date.

Key entities

  • Latham Group, Inc.

    Company subject of the Form 4 insider transaction disclosure (SWIM).

  • Kunchala Suraj

    Vice President and Controller who sold 8,693 shares to the issuer at $7.2900 on 2026-08-07.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Latham Group Refinances Capital Structure with New Credit Facilities

Latham Group (SWIM) refinanced its capital structure with new credit facilities totaling $375 million. The facilities include a $75 million revolving credit line and a $300 million term loan, both secured by company assets. Proceeds were used to repay existing debt. The facilities mature in 2031 and 2033, respectively, and include leverage-based interest margins and covenants.

$HOWLHighAI 8/10

Latham & Watkins Advises on Oversubscribed US$150 Million Private Placement in Connection With Werewolf Therapeutics and Ambros Therapeutics’ Reverse Merger Transaction

Werewolf Therapeutics (HOWL) and Ambros Therapeutics agreed to merge in an all-stock deal. The combined company will focus on Ambros' neridronate program for CRPS-1 and trade as AMBX. They secured $150M in private placement from healthcare investors. Latham & Watkins advised on the transaction.

$GOSSHighAI 9/10

Latham Advises Gossamer Bio on Up to US$250 Million Structured Private Placement, Including US$150 Million of Committed Capital

Gossamer Bio (GOSS) plans a private placement of up to $250M, including $150M committed capital. The deal involves new and existing investors and is contingent on FDA actions for seralutinib. Latham & Watkins advised the company. The financing follows Gossamer's reacquisition of seralutinib rights and precedes its planned NDA submission in September 2026.

MedAI 8/10

Latham & Watkins Advises on Andersen Group’s US$188.5 Million Secondary Offering

Andersen Group Inc. announced a secondary offering of 4.28 million shares of Class A common stock at $44 per share, with gross proceeds of $188.5 million for selling stockholders. The offering is expected to close on August 21, 2026, with underwriters having a 30-day option to purchase additional shares. Andersen is not selling shares and will not receive proceeds. Latham & Watkins LLP represents the underwriters.